Media Home
UN Web TV
UN Audiovisual Library
UN PhotoWHO / EBOLA EXPERTS MEETING
Download
There is no media available to download.
Share
STORY: WHO / EBOLA EXPERTS MEETING
TRT: 1.40
SOURCE: WHO
RESTRICTIONS: NONE
LANGUAGE: ENGLISH
DATELINE: 4 SEPTEMBER 2014, GENEVA, SWITZERLAND
1. Pan left, screen with meeting name to participants
2. Med shot, check in desk
3. Wide shot, table with materials
4. Wide shot, meeting room
5. Close up, screen
6. SOUNDBITE (English) Dr Marie-Paule Kieny, WHO Assistant Director-General - Health Systems and Innovation:
“What is the plan, what can we all do in order to have this unproven medicine, and I want to stress this point, what we will be discussing at this moment is unproven. This is the hope of what we are going to have. How are can we take the thing that are the most promising of these unproven medical products and make sure that they are developed with the highest speed possible. So developed in terms of getting them to registration and developed in terms of putting them in the treatment centre as much as possible in order to make a difference in the lives of people.”
7. Pan right, meeting room
8. SOUNDBITE (English) Dr Marie-Paule Kieny, WHO Assistant Director-General - Health Systems and Innovation:
“We will go into the plan, from the plan, what support is needed, from everybody. From governments, from funding agencies, how can we have this plan move this unproven medicine to medicines that are experimented in the field to make an impact possibly on the epidemic, but certainly also on the lives of the people who have to fight the epidemic.”
The World Health Organization (WHO) has brought together key experts to discuss experimental therapies and vaccines with potential to treat or prevent Ebola virus disease.
Participants at the Geneva meeting will include technical experts from companies and organizations developing Ebola interventions and policymakers from Ebola-affected countries, ethicists, clinicians, researchers, regulators, and patient representatives.
A range of interventions, which include blood products, immune therapies, drugs and vaccines, are under different stages of development. None have yet been licensed for clinical use.
In early August, an expert panel convened by WHO concluded that, in the particular circumstances of the current outbreak, and provided certain conditions are met, it is ethical to offer unproven interventions as potential treatments or for prevention of infection.
